A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2019
Price : $35 *
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- 11 Apr 2019 Status changed from recruiting to suspended.
- 02 Oct 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 Planned initiation date changed from 28 Jul 2018 to 28 Sep 2018.